Medical Crossfire®: How Has the Nurse's Role Evolved in the Management of Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas?

Overview

Management of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN) is rapidly evolving with a growing number of available treatment options. Appropriate treatment strategies should be carefully considered in the context of emerging clinical trial data to develop individualized and collaborative care plans to optimize patient outcomes.

This Medical Crossfire® program brings together clinical experts to highlight the clinical relevance of the multidisciplinary care team in the management of pediatric patients with NF1 and PN, to discuss the current and emerging treatment options for NF1 and associated toxicity management, and to provide a forward-looking perspective on the future of treatment for pediatric patients with NF1 and PN. The program features panel-based patient case discussions surrounding innovative management and patient advocacy strategies and practical, tailored approaches to the treatment of pediatric patients with NF1 and PN.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Summarize the pathophysiologic factors underlying neurofibromatosis type 1 and plexiform neurofibromas relevant to counseling conversations with patients and caregivers
• Provide the rationale for recommendations for use of specific treatments and medical interventions among patients with type 1 and plexiform neurofibromas
• Assess recent trial evidence and methods to manage treatment-related toxicities with the use of MEK1/2 inhibition strategies in neurofibromatosis type 1 and plexiform neurofibroma care settings

Program Chair

Roger Packer, MD

To view full profile, click on the Program Chair tab above.